Japanese medaka (Oryzias latipes) were continually exposed in a ow-through diluter system for 9 months to measured bromodichloromethan e (BDCM) concentrations of 0.018, 0.143, or 1.424 mg/L. Parameters evaluated were hepatocarcinogenicit y, hepatocellular proliferation, hematology, and intrahepatic BDCM concentration . BDCM was not hepatocarcinogeni c to medaka at the concentration s tested. Chronic toxicity was evidenced at 6 and 9 months by statistically signi cant (a 0.05) levels of gallbladder lesions and bile duct abnormalities in medaka treated with 1.424 mg/L BDCM. Hepatocellular proliferation was assessed after 1, 4, and 20 days of BDCM exposure. Treatment-related increases or decreases in cellular proliferation were not observed at any time point. Hematocrit, leukocrit, cell viability, and cell counts of treated sh after 9 months of BDCM exposure were not signi cantly different from control sh. Intrahepatic concentration s were evaluated by gas chromatograph y after 9 months of BDCM exposure. Fish livers from all three BDCM treatments had detectable amounts of BDCM, with median intrahepatic concentration s of 1.02, 2.89, and 21.25 mg BDCM/kg sh liver in the low, middle, and high concentrations , respectively. Medaka chronic toxicity effects of statistically signi cant gallbladder and bile duct abnormalities occurred at 1.424 mg/L BDCM, well above median drinking water levels.
INTRODUCTION
Bromodichloromethane (BDCM) and chloroform are trihalomethanes that are 2 of the most frequently found drinking water disinfection by-products. Previous National Toxicology Program (NTP) rodent research with BDCM corn oil gavage exposure has found adenocarcinoma of the large intestine in male rats (50 and 100 mg/kg), kidney tumors in male mice (25 and 50 mg/kg), and liver tumors in female mice (25 and 50 mg/kg) (16) . Based on these studies, the U.S. Environmental Protection Agency (EPA) issued a nal maximum contaminant level goal (MCLG) for BDCM of 0 (23) .
In the NTP rodent studies, the route of BDCM exposure was gavage, not via drinking water, and the exposure concentrations were several orders of magnitude above BDCM levels found in disinfected drinking water. A need existed to perform animal studies at BDCM concentrations closer to drinking water levels (1) . Although the level of BDCM in drinking water varies dependent upon the components of the source water and the kind of disinfection process, Borum et al recently reported a median BDCM concentration of 0.0067 mg/L for 7 Utah utilities over a 2-year period (2) .
Alternative animal models such as sh are a natural choice for testing aqueous solutions. Fish have been shown to be sensitive to trace levels of contaminants in aquatic media (8, 15, 17, 22, 24) . As water-dwelling organisms, sh are immersed in the exposure solution, with dosing occurring through dermal, oral, and most signi cantly, through respiratory routes.
Japanese medaka sh (Oryzias latipes) are an attractive test model because they are hardy, small in size, easy to culture, and have a relatively short time-to-tumor response. Medaka are reproductively mature at 3 months of age, and an exposure duration of 9 months encompasses the majority of the active growth and development phase of the sh life cycle. Sections of the entire animal will t on 2 to 3 microscope slides so that examination of each tissue is possible in its anatomical context. The low rate of spontaneous neoplasms in medaka ( 0.3%) aids in the interpretation of bioassay results (10) .
The objective of this study was to determine the effect of BDCM on Japanese medaka after 9 months of continuous exposure. Speci c endpoints examined were histopathology, to include the severity and prevalence of neoplasms, hepatocellular proliferation, hematology, intrahepatic BDCM concentration, sh growth, and sh survival. A stock solution of 160 mg/L BDCM was made by adding 0.1 mL of neat BDCM to each liter of processed well water. The BDCM stocks were stirred for 24 2 h in sealed glass containers, then pumped into a diluter dosing bottle. Approximately 12 L of BDCM stock were needed for each test day.
MATERIALS AND METHODS
The 5-bromo-2 -deoxyuridine (BrdU)(CAS No. 59-14-3) of 99% purity was obtained from Sigma Chemical Co, St. Louis, MO. BrdU is water soluble, nonvolatile, and stable under test conditions. A stock solution of 10 g/L BrdU was prepared in ASTM Type I water on the day of exposure.
Animal Care: Research was conducted in compliance with the Animal Welfare Act, and other Federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the 1996 Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC), in facilities that are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International.
Japanese medaka sh were supplied from the U.S. Army Center for Environmental Health Research (USACEHR) inhouse cultures and were reared according to USACEHR Standing Operating Procedures, as described previously (20) . Fish culture conditions were: a water temperature of 25 1 C, water ow of 100 mL/min of an aerated, hard, processed groundwater, an 18/6-hr light/dark cycle with full spectrum uorescent lighting, and an age-related amount of sh ake food and live brine shrimp fed daily. Medaka were selected for testing at age 14 days 1 day and were fed throughout the study. Fish were fasted 24 h prior to the 6-and 9-month histopathology sacri ces and the BrdU exposures.
Test Design: Although the amount of BDCM routinely found in dechlorinated tap water is 0.0067 mg/L (2), a slightly higher BDCM concentration of 0.015 mg/L was chosen as the lowest concentration to be tested so that the results from this study could be compared to a previous medaka study with chloroform (20) . In 96-h range-nding studies with juvenile medaka, a standard length "No Observed Effect Level" (NOEL) of 15-19 mg/L and a wet weight NOEL of 6 to 7 mg/L were estimated for BDCM (19) . A log scale was chosen for the 3 concentrations of BDCM, which ensured that all concentrations tested were below the NOELs established in acute testing. A solenoid-controlled proportional diluter with 2 sealed mixing chambers for each of 4 BDCM concentration levels delivered the required concentrations to the test aquaria. Two pairs of test aquaria were randomly assigned to each nominal concentration: 0, 0.015, 0.15, and 1.5 mg/L BDCM. The test began when 14-day-old fry ( 1 day) were randomized to each test aquarium, with 80 fry per aquarium. The diluter was set to deliver 300 15 mL to each aquarium every 3 min 15 seconds, yielding 9 to 10 tank volume turnovers per day.
A summary of the experimental design is shown in Table 1 . At 3 timepoints during the rst month of BDCM exposure, 5 sh per aquarium per timepoint were used for hepatocellular proliferation assays. After 6 months of BDCM exposure, 20 sh per aquarium were used for histopathologica l evaluation. At 9 months of exposure, 5 sh per aquarium were used for the BDCM intrahepatic concentration analysis, and another 5 sh were used for basic hematological evaluation. All remaining sh were processed for assessment of the following tissues by histopathology : bone (vertebra), brain, chromaf n tissue, corpuscle of Stannius, esophagus, eye, gallbladder, gill, heart, hematopoietic tissue, interrenal tissue, intestine, kidney, liver, nares, ovary, pancreas, peripheral nerve, pineal organ, pituitary gland, pseudobranch, skeletal muscle, skin, spinal cord, spleen, stato-acoustic organ, swim bladder, testis, thymus, thyroid tissue, urinary bladder, and gross lesions.
Statistical Analyses: Lengths, weights, and histopathology data were analyzed statistically for the chronic carcinogenicity test. For these and all other test endpoints, normalizing transformations were applied, where required, and the best-tting model was selected for each endpoint. Analysis of variance (ANOVA) was used to test for effects, and regression analysis was used for point estimation. SAS PROC GLM computer software was used for these analyses (18) .
BDCM Chemical Analyses: All exposure tanks were sampled weekly and analyzed on the day of collection. Daily stock solutions were collected, stored at 5 1 C, and analyzed weekly. Samples were collected in 40-mL borosilicate glass EPA water sampling vials with Te on-lined silicone rubber septa in the cap. Sample analysis has been described previously (20) . Brie y, triplicate 5-mL aliquots of the 40-mL samples were analyzed using a Hewlett Packard 6890 gas chromatograph equipped with an electron capture detector and interfaced to a Hewlett Packard model 7694 headspace sampler. The average percent recovery was 92%.
BrdU Chemical Analyses: Samples for chemical analysis were collected at the initiation and termination of each exposure. Spiked samples showed an average percent recovery of 98%. The methods for BrdU analysis have been published previously (3, 20) .
Brie y, samples were ltered through a 0.45-um membrane before triplicate 10 uL samples were injected onto a Hewlett Packard 1050 series High Performance Liquid Chromatograph equipped with a variable wavelength detector, autosampler, and Hewlett Packard Chemstation. Measured BrdU results from exposure initiation and termination samples were averaged to determine the mean concentration for each test group.
Hepatocellular Proliferation Assays: BrdU exposure procedures have been described previously by Brennan et al (3) . Brie y, 5 sh per aquarium were removed from each of the 16 test aquaria on BDCM exposure days 1, 4, or 20, exposed to 75 mg/L BrdU for 72 4 h, euthanized with an overdose of MS-222, opened from anal vent to the gills and placed in 10% neutral buffered formalin.
A Bioquant R /True Color Image Analysis System was used to evaluate 5 BrdU-stained sections from each sh. A count labeling index (CLI) was done to validate the area labeling index (ALI) method and to ensure that hepatic cell size did not change due to the BDCM exposure. R 2 values for comparison of CLI to ALI for the 1-, 4-, and 20-day endpoints were 0.9805, 0.9447, and 0.9040, respectively.
Chronic Histopathology: At 6 and 9 months of BDCM exposure, sh were euthanized with an overdose of tricaine methane sulfonate (MS-222). Fish necropsy procedures, xation, sectioning, staining, and histopathology were as described previously (21) . Brie y, sh were opened ventrally, ushed with Bouin's solution, and sealed in tissue cassettes. After 48-hr immersion in Bouin's, the tissue was rinsed with 2 successive 24-hr treatments of 70% ethanol, then held in 10% formalin. Five longitudinal step sections were cut from paraf n blocks, stained with hematoxylin and eosin, followed by microscopic evaluation of the tissue.
Fish Hematology: At the 9-month timepoint, 5 sh per aquarium were removed from the exposure system. The sh were euthanized, weighed, and measured. A capillary tube (5-10 uL) of blood was removed from each sh, and each medaka's pronephric tissue, a major site of hematopoeisis, was excised. Hematocrit and leukocrit were measured for each sample. A hemacytometer was used to determine kidney cell counts. Trypan blue exclusion was used to assess kidney cell viability.
Fish Intrahepatic BDCM Concentration: After 9 months of BDCM exposure, 5 sh per aquarium were removed from the test for analysis of BDCM intrahepatic concentration. Fish livers were excised, weighed, and ash-frozen in individual cryovials in liquid nitrogen, and then stored at 70 C until analysis. Thawed livers were individually denatured in 5 mL of 2% (w/v) sodium dodecyl sulfate at 60 C for 2 h. Headspace analysis by capillary gas chromatography immediately followed. The detection limit for this gas chromatography method was 0.001 mg/ L and the percent recovery was 92%.
RESULTS
Water Quality: Test water quality parameters monitored were temperature, pH, dissolved oxygen, conductivity, alkalinity, hardness, and un-ionized ammonia. All water quality parameters were found to be within acceptable limits based on over 10 years of historical data of our laboratory diluent water.
BDCM Chemical Analyses: Over the course of 9 months, 39 weekly chemical analyses were performed on each aquarium. Mean measured concentrations (replicates combined) yielded mean measured test concentrations and standard deviations of 0, 0.018 0.008, 0.143 0.029, and 1.424 0.233 mg/L. Hepatocellular Proliferation Assays: No mortality occurred during any of the three 72-h BrdU assays. Mean measured BrdU concentration and standard deviation for all treatments was 74.8 1.4 mg/L. Results from all 3 assays suggested no treatment-related effects of BDCM on hepatocellular proliferation at any of the concentrations tested (after 20 d of BDCM exposure, treatment mean BDCM levels were 0.018, 0.0885, and 0.993 mg/L).
Fish Growth and Survival: Mortality through the 9-month exposure period was < 4% in all control and treated groups. Growth measurements are summarized in Table 2 . ANOVA indicated that there were no BDCM treatment effects for length or weight at 6 months (p 0.2913; p 0.6725) or at 9 months ( p 0.8485; p 0.5456).
Fish Histopathology : At 6 months of BDCM exposure, ANOVA indicated that the signi cant ndings for males were hyperplasia (proliferation) of gallbladder epithelium ( p 0.0002), concretions in the gallbladder ( p 0.0046), concretions in the bile ducts of the liver ( p 0.0051), dilatation of bile ducts ( p 0.0001), and hyperplasia of bile ducts ( p 0.0076). In contrast, females demonstrated 1 signi cant nding and 2 marginal ndings for the 6-month interim necropsy: concretions in the gallbladder ( p 0.0001), concretions in the bile ducts ( p 0.0753), and dilatation of the bile ducts ( p 0.0753).
For sh histopathology at 9 months, ANOVA showed there were signi cant differences in males (Tables 3 and 5) exposed to BDCM for concretions in the gallbladder ( p 0.0460), dilatation of bile ducts ( p 0.0439), and for hyperplasia of bile ducts ( p 0.0078). Females (Tables 4 and 5 ) responded to increased measured BDCM levels with increased hyperplasia of gallbladder epithelium (p 0.0001), concretions in the gallbladder ( p 0.0001), concretions in the bile ducts ( p 0.0067), and dilatation of the bile ducts ( p 0.0001). BDCM effects were found to be signi cant only at 1.424 mg/L, the highest BDCM exposure level, according to comparisons made among treatment groups using regression point estimates and their associated 95% con dence limits.
There were no liver neoplasms observed for control or treated sh at 6 months. At 9 months, lymphosarcoma (at 1.464 mg/ L BDCM level), papilloma of the gallbladder (0.018 mg/L BDCM), tubular carcinoma of the kidney (0 mg/L BDCM), and hepatocellular carcinoma of the liver (0.018 mg/ L BDCM) occurred in single medaka and appeared independent of test concentration.
Trends seen in the occurrence of gallbladder lesions and bile duct abnormalities at 6 months were con rmed at 9 months. Representative photomicrographs of tissue alterations occurring at the 1.424 mg/L level of BDCM are shown in Figure 1 . Table 5 shows relevant ndings at 6 and 9 months where responses were observed. In males, ndings of concretions in the gallbladder, dilatation of the bile ducts, and hyperplasia of bile ducts at 6 months were veri ed at 9 months whereas ndings of hyperplasia of gallbladder epithelium and concretions in bile ducts were not. In females, concretions in the gallbladder were the only nding present at both the 6-and 9-month sacri ce. Hyperplasia of gallbladder epithelium was not evident for females at 6 months but was a signi cant nding at 9 months. Two ndings, concretions in bile ducts and dilatation of bile ducts, were of marginal signi cance for females at 6 months but both were signi cant at 9 months.
Fish Hematology Test: The hematology analysis was conducted at 9 months of BDCM exposure. ANOVA performed on data from BDCM-treated sh for hematocrit, leukocrit, cell viability, and cell count demonstrated that none of these parameters were signi cantly different from controls (p 0.05).
Fish Intrahepatic Concentration: BDCM was not detected in any of the 20 sh livers from the 0 mg/L aquaria concentration group. Twelve of the 20 sh analyzed in the 0.018 mg/L aquaria concentration group had measurable amounts of BDCM (range 0.41 to 1.85 mg BDCM/kg of sh liver). At the 0.143 mg/L BDCM concentration, 20 out of 20 sh livers had measurable amounts of BDCM (range 1.38 to 6.25 mg/kg). At the 1.424 mg/L aquaria BDCM concentration, 20 sh livers out of 20 sampled had detectable amounts of BDCM (10.5 to 45.7 mg/kg). Fish with intrahepatic BDCM concentrations greater than the external exposure concentration occurred in 12 out of 20 sh in the low concentration group, and in 20 of 20 sh in each of the higher BDCM concentrations. A representative chromatogram of a 1.424 mg/L exposed sh liver sample is shown in Figure 2 .
DISCUSSION
A positive association has been noted in rodent studies between increased cell proliferation and hepatocarcinogenicity induced by such structurally diverse chemicals as 2-nitropropane and diethylnitrosamine (6, 13) . This association was also seen in medaka (9) after a 48-h exposure to the liver carcinogen diethylnitrosamine. Neither early increased liver cell proliferation nor treatment-related carcinogenicity was found in sh in the present study, however, treatmentrelated gallbladder and bile duct changes were observed.
Concretion occurrence in gallbladder and bile ducts has previously been identi ed in chloroform-treated medaka (20) . Gallstones of unknown signi cance or etiology have also been identi ed in tilapia (Oreochromic mossambicus) (7) . The occurrence of biliary concretions has been noted in monkeys, cattle, and pigs with an origin of a crystallization nidus (12) . It was suggested that a nidus might result from an infectious agent such as Pseudomonas aeruginosa, which has been identi ed as the causative agent of concretions in sheep, or from particles of bile salts, calcium carbonate, cholesterol, or precipitated bilirubin.
In both the chloroform and the current BDCM study, there was no evidence of altered immune function, no decrease in hematocrit levels, and microscopic examination did not reveal evidence suggesting the presence of an infectious agent. The origin of these concretions may be chemical in nature but further studies are needed to explore their etiology. In addition to no histological suggestion of infectious agent, no early hepatocellular proliferation, no liver necrosis, no statistically signi cant liver neoplasia, and no marked growth impairment within treatment groups among sh with statistically significant pathology were noted. In light of these ndings, it is unclear what, if any, effect these bile duct and gallbladder changes has for these chronically exposed sh.
The agreement between the previous chloroform (20) study and the current BDCM ndings regarding concretion histological ndings is of interest considering that treatment levels of chloroform and BDCM were of the same order of magnitude, and the route of exposure was identical. Additionally, both chloroform and BDCM are chemically similar trihalomethanes. The nding of concretions from exposure to these two drinking water disinfectant by-products may be related to similar toxicity mechanisms for chloroform and BDCM. Interestingly, Melnick et al (14) , found that dose responses were remarkably similar for liver weight, serum sorbitol and alanine aminotransferase activities, hepatocyte degeneration, and hepatocyte labeling index in female mice receiving daily (5 times per week for 3 weeks) gavage doses of 10 mL/kg of body weight of either chloroform or BDCM.
It is dif cult to compare the results of BDCM exposure between medaka and rodents due to differences in BDCM concentration and route of administration in the 2 vertebrate models (gavage for rodents, ambient water for sh). Within rodent studies, trihalomethanes are more toxic when administered by gavage than by drinking water at the same concentrations (5) . BDCM concentration levels in the present study were near the drinking water concentration levels of BDCM, whereas the rodent study used much higher concentration levels.
The chromatogram from the BDCM intrahepatic concentration study does not show any unknown peaks of the same magnitude as the BDCM peak. This was not the case in a previous study with chloroform, where a large peak was discernible between the injection peak and the chloroform peak (20) . When the average intrahepatic BDCM concentrations in medaka were compared among treatment groups (1.02 mg/kg for 0.018 mg/L BDCM, 2.89 mg/kg for 0.143 mg/ L BDCM, and 21.25 mg/kg for 1.424 mg/L BDCM), the lowest BDCM external concentration proportionally had the highest BDCM intrahepatic levels. Of the 12 livers in the lowest BDCM treatment group that had detectable levels of BDCM, the measured value of each sample was 0.002 mg/L, which is near the instrumental detection limit of 0.001 mg/L. One factor contributing to the high variability among all treatment groups is the range of liver wet weights (2 to 16 mg), which is typical of a mixed gender population. Test animals were randomized at an early age where sexual differentiation was not readily apparent by gross external observation.
Early studies by the USACEHR and colleagues are underway to develop a physiologically based pharmacokinetic (PBPK) model for trihalomethanes with medaka, to aid in the understanding of the mechanistic events associated with how these concretions in the gallbladder and bile ducts are formed. The critical studies regarding BDCM and chloroform metabolism and their associated molecular sequlae in medaka remain to be accomplished, however.
Reports in the literature indicate that basophilic foci in medaka are often likely to develop into hepatocellular adenomas (4, 11) . Foci of cellular alteration, including basophilic foci, occurred in this study independent of chemical concentration. At the lowest concentration tested in the current study, eosinophilic foci occurred in 3/113 (2%) sh, whereas basophilic foci occurred in 1/113 (1%) of the sh. This low level of occurrence was not statistically signi cant and has been seen in control (unexposed) medaka in a previous 9-month test at USACEHR using the same diluent water (21) . The lack of tumors at higher BDCM levels in the current study leads one to believe that these foci of cellular alteration may be of spontaneous origin and unrelated to BDCM treatment. Regardless of their actual pathological signicance, the appearance of basophilic foci in this study was not associated with any increased prevalence of hepatic or biliary neoplasia.
Statistically signi cant ndings of tissue abnormalities in both the gallbladder and the liver at chemical concentrations of 1.4 mg/L were observed in this study and in a previous USACEHR study with chloroform (20) . Because these abnormalities were not seen at concentrations 1 to 2 orders of magnitude below 1.4 mg/ L of either BDCM or chloroform, it is likely that the 1.4 mg/L may approximate a threshold concentration for the physiologic processes leading to concretion formation in medaka. Based on these ndings of gallbladder and liver abnormalities, a follow-up chronic BDCM study with sh has been initiated to examine the tumor promotion potential of BDCM using a low dose diethylnitrosamine (DEN) initiation step prior to the BDCM exposure.
Although BDCM was not acutely toxic to medaka at concentrations 2 or 3 orders of magnitude above median drinking water levels, chronic toxicity effects of BDCM were evidenced by statistically signi cant ndings in the gallbladder and bile ducts of sh treated with 1.424 mg/L BDCM in this study. The future studies combining dose evaluations with an initiation/promotion protocol in chronic exposures at and above the concentrations tested in this study should provide valuable insights into the toxic effects of BDCM. Future studies of the etiology and signi cance of the concretion formation observed in this study should also be informative.
